Trial
NCT02934503
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
Merck Sharp & Dohme LLC
Condition
Small Cell Lung Cancer (SCLC)
Intervention
Pembrolizumab
Why stopped
This study was terminated as the standard of care for small cell lung cancer changed in 2018 to include immunotherapy in the front line setting, making this study no longer clinically relevant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-16